Reported 1 day ago
Maziar Mike Doustdar, a longtime insider at Novo Nordisk, has been appointed CEO with the mission to revitalize the company after a significant decline, losing two-thirds of its value in the past year. Facing tough competition, particularly from Eli Lilly's weight-loss drug, Doustdar promises swift actions, including potential cuts, to realign the company while navigating challenges, such as supply issues and regulatory scrutiny. His leadership comes at a vital time for the Danish pharmaceutical giant, which is crucial to Denmark's economy.
Source: YAHOO